SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Paracelsian Inc (PRLN)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Rick Costantino who wrote (341)8/29/1996 10:26:00 PM
From: Michael Yang   of 4342
 
Rick,

I think it is only fair to let journals publish the scientific finding s and details. Some companies or research institutions release data via press conference or influential paper such New York Times. (We joke that is publication in the JNYT.) This conference call is something like a press conference, but the management was bound by some agreement so they can not talk about specific data, such as inhibition of the c-mos kinase.

What surprised me was that three different pathways (two were discovered by PRLN) are involved in HIV killing of the T-cells. So the c-mos participates in one. I assume that these cell lines can be patented. But theoretically, once somebody knows the pathways PRLN is working on, they can duplicate the effort. However, PRLN may be in possesion of the unique herb/compound that could be sold in one year.

I am not worried about how PRLN would get the publicity for the dietary supplement that cures AIDS.

Michael
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News